KalVista Pharmaceuticals (KALV) Other Accumulated Expenses (2016 - 2024)
Historic Other Accumulated Expenses for KalVista Pharmaceuticals (KALV) over the last 8 years, with Q4 2024 value amounting to $693000.0.
- KalVista Pharmaceuticals' Other Accumulated Expenses changed N/A to $693000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $693000.0, marking a year-over-year change of. This contributed to the annual value of $253000.0 for FY2024, which is N/A changed from last year.
- KalVista Pharmaceuticals' Other Accumulated Expenses amounted to $693000.0 in Q4 2024.
- In the past 5 years, KalVista Pharmaceuticals' Other Accumulated Expenses ranged from a high of $1.3 million in Q3 2024 and a low of $47000.0 during Q3 2020
- Its 4-year average for Other Accumulated Expenses is $315916.7, with a median of $200500.0 in 2023.
- As far as peak fluctuations go, KalVista Pharmaceuticals' Other Accumulated Expenses tumbled by 8199.23% in 2020, and later surged by 78783.78% in 2024.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Other Accumulated Expenses stood at $78000.0 in 2020, then soared by 58.97% to $124000.0 in 2021, then soared by 153.23% to $314000.0 in 2023, then surged by 120.7% to $693000.0 in 2024.
- Its Other Accumulated Expenses stands at $693000.0 for Q4 2024, versus $279000.0 for Q4 2024 and $1.3 million for Q3 2024.